Stimcell Energetics Inc. (STME) stock: key figures, P/E, revenue and dividend

Health Care · Canada

Price
0.23 USD
Market cap
4.81 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
49.43 %
Return on assets (ROA)
-1,099.24 %

Stimcell Energetics Inc. financials

Fiscal year20252026
EBIT-528,037.00 USD-826,027.00 USD
Net income-566,293.00 USD-895,375.00 USD

Full history since 2010, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Stimcell Energetics Inc.

StimCell Energetics Inc., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, metabolic syndrome, neuropathy, and kidney functions in the United States. It develops and manufactures the eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and the eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual. The company also develops eBalance Home and eBalance Pro System for temporary relief of the shoulder, waist, back, neck, upper and lower extremities (arms and legs). The company was formerly known as Cell MedX Corp. and changed its name to StimCell Energetics Inc. in November 2024. StimCell Energetics Inc. was incorporated in 2010 and is headquartered in Vancouver, Canada.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.